ChemFaces is a professional high-purity natural products manufacturer.
Product Intended Use
1. Reference standards
2. Pharmacological research
Citing Use of our Products
How to Order
Orders via your E-mail:
1. Product number / Name / CAS No.
2. Delivery address
3. Ordering/billing address
4. Contact information
Sent to Email: firstname.lastname@example.org
Order & Inquiry & Tech Support
Address: No. 83, CheCheng Rd., WETDZ, Wuhan, Hubei 430056, PRC
Delivery & Payment method
1. Usually delivery time: Next day delivery by 9:00 a.m. Order now
2. We accept: Wire transfer & Credit card & Paypal & Western Union
* Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.
According to end customer requirements, ChemFaces provide solvent format. This solvent format of product intended use: Signaling Inhibitors, Biological activities or Pharmacological activities.
|Size /Price /Stock
||10 mM * 1 mL in DMSO / $7.0 / In-stock||Other Packaging
||*Packaging according to customer requirements(100uL/well, 200uL/well and more), and Container use Storage Tube With Screw Cap
More articles cited ChemFaces products.
Mol Med Rep.2014, 9(5):1653-9Exp Parasitol.2015, 153:160-4Acta Pharm Sin B.2015, 5(4):323-9.Acta Biochim Pol.2015, 62(2):253-8J Pharm Biomed Anal.2016, 129:50-59Asian J Beauty Cosmetol...2016...J Med Food.2016, 19(12):1155-1165J of Engineering Science&Technolo...2018...
Mol Pharm.2018, 15(8):3285-3296Korean J. Medicinal Crop Sci....2018...RSC Adv.2018, 32621-32636J Herbmed Pharmacol.2018, 7(4):280-286J Mol Med (Berl).2018, 96(7):661-672J Sci Food Agric.2018, 98(3):1153-1161J Ethnopharmacol.2019, 235:406-414J Ethnopharmacol.2019, 244:112074
Food Chem.2019, 290:286-294Int J Immunopathol Pharmacol....2019...Biochem Biophys Res Commun....2019...Cell Physiol Biochem....2019...Antioxidants (Basel).2019, 8(8):E307Biomolecules.2019, 9(11):E696Biomolecules.2020, 10(2):E184
Our products had been exported to the following research institutions and universities, And still growing.
Instituto de Investigaciones Ag... (Chile)Utah State University (USA)Fraunhofer-Institut für Moleku... (Germany)University of Liège (Belgium)
Ain Shams University (Egypt)CSIRO - Agriculture Flagship (Australia)University of Malaya (Malaysia)Center for protein Engineering ... (Belgium)
Lodz University of Technology (Poland)University of East Anglia (United Kingdom)Korea Food Research Institute(K... (Korea)
Related Screening Libraries
||Levodopa is the precursor to the neurotransmitters dopamine, norepinephrine (noradrenaline), and epinephrine (adrenaline), used to treat Parkinson's symptoms.|
|Malays J Med Sci. 2014 Dec;21(Spec Issue):6-11. |
|Evaluation of the Cytotoxicity of Levodopa and its Complex with Hydroxypropyl-ß-Cyclodextrin (HP-ß-CD) to an Astrocyte Cell Line.[Pubmed: 25941458]|
METHODS AND RESULTS:
A simple, reliable a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-phenyl)-2-(4-sulfophenyl)-2H-tetrazolium, (MTS) assay was conducted to evaluate the potential cytotoxic effects of Levodopa, a "gold standard therapy" for Parkinsonism, and its complex with Hydroxypropyl-β-Cyclodextrin (HP-β-CD) on an astrocyte cell line. The cells were incubated in a range of concentrations from 4.69 to 300 μg/mL Levodopa, HP-β-CD or the complex for up to 72 hours. At every 24-hour interval, the optical density (OD), which reflects the number of viable cells, was recorded. In general, linear dose-dependent cytotoxicity profiles were observed for the cells subjected to Levodopa or the complex, whereas a slightly triphasic response was observed for the cells exposed to HP-β-CD. A significant difference (P < 0.05) in cytotoxicity was detected between the HP-β-CD-treated group and the Levodopa-treated group.
In particular, we observed that the cells treated with the complex, even at the highest concentrations (> 200 μg/mL), exhibited improved tolerability in a time-dependent manner, which may indicate the potential ability of HP-β-CD to mask the toxic effects of Levodopa via complexation.
|Zhonghua Yi Xue Za Zhi. 2015 Feb 17;95(7):493-5. |
|[Effects of a single dose levodopa on heart rate variability in Parkinson's disease].[Pubmed: 25916922]|
To explore the effects of Levodopa on heart rate variability (HRV) in Parkinson's disease (PD).
METHODS AND RESULTS:
A total of 48 PD patients (M:F = 35: 13, mean age: 59 ± 6 years, duration of illness: 4.7 ± 1.8 years, Hoehn & Yahr stage: 2.2 ± 0.3) on a stable dose of Levodopa were recruited from January 2012 to May 2014.For confirming autonomic dysfunction, the baseline patient data (12 hours off-medication) were compared with a control group consisting of 48 age and gender-matched healthy subjects (M: F = 35: 13, mean age 58 ± 6 years). Resting lead II electrocardiogram (ECG) was recorded at baseline and continuously after two tablets of 100/10 mg Levodopa/carbidopa.However, 5-min segments were selected from every quarter, i.e., Q1 (0-15 min), Q2 (15-30 min), Q3 (30-45 min) and Q4 (45-60 min). Artifact-free 5-min segments of ECG were analyzed offline to acquire the parameters of heart rate variability in time and frequency domains.
At baseline, PD patients had a significantly reduced standard deviation of normal-to-normal intervals (SDRR) [(24 ± 4) vs (26 ± 4) ms, P < 0.01)] and total power (TP) [(569 ± 180) vs (652 ± 205) ms2, P < 0.05] when compared to controls. Comparing of HRV in PD patients at baseline and during first hour after drug administration, we observed significant increase in SDRR [(29 ± 12) vs (24 ± 8) ms, P < 0.05)], TP [(708 ± 253) vs (569 ± 180) ms2, P < 0.01], low frequency power (LF) [(203 ± 98) vs (168 ± 60) ms2, P < 0.05) ] and high frequency power (HF) [158 ± 86) vs (114 ± 90) ms2, P < 0.05] in Q3.
The results suggest an improvement in the overall variability of heart rate resulting from an enhanced vagal tone.
||The seeds of Mucuna sempervirens Hemsl.
||Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
||Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: email@example.com
||The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
Recent ChemFaces New Products and Compounds
Recently, ChemFaces products have been cited in many studies from excellent and top scientific journals
Cell. 2018 Jan 11;172(1-2):249-261.e12. doi: 10.1016/j.cell.2017.12.019.IF=36.216(2019)PMID: 29328914
Cell Metab. 2020 Mar 3;31(3):534-548.e5. doi: 10.1016/j.cmet.2020.01.002.IF=22.415(2019)PMID: 32004475
Mol Cell. 2017 Nov 16;68(4):673-685.e6. doi: 10.1016/j.molcel.2017.10.022.IF=14.548(2019)PMID: 29149595
ACS Nano. 2018 Apr 24;12(4): 3385-3396. doi: 10.1021/acsnano.7b08969.IF=13.903(2019)PMID: 29553709
Nature Plants. 2016 Dec 22;3: 16206. doi: 10.1038/nplants.2016.205.IF=13.297(2019)PMID: 28005066
Sci Adv. 2018 Oct 24;4(10): eaat6994. doi: 10.1126/sciadv.aat6994.IF=12.804(2019)PMID: 30417089
Calculate Dilution Ratios(Only for Reference)
* Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
|Physiol Behav. 2015 Apr 23;147:193-197. |
|Coadministration of hydroxysafflor yellow A with levodopa attenuates the dyskinesia.[Pubmed: 25914172]|
|Levodopa (L-DOPA) is used as the most effective drug available for the symptomatic treatment of Parkinson's disease (PD). However, long-term treatment of Levodopa frequently causes complications, including abnormal involuntary movements such as dyskinesia and response fluctuations in PD patients.
METHODS AND RESULTS:
In the present work, we investigated whether hydroxysafflor yellow A (HSYA) ameliorates Levodopa-induced dyskinesia and motor fluctuations in the 6-hydroxydopamine-lesioned rat model of PD. Valid PD rats were treated daily with vehicle, HSYA alone, Levodopa, or a combination of HSYA plus Levodopa for 21days, respectively.Levodopa(8mg/kg) and benserazide (15mg/kg) were treated intraperitoneally. HSYA was administrated intraperitoneally at a dose of 10mg/kg. The abnormal involuntary movements and rotational behavior were evaluated. The expression of the dopamine D3 receptor in the striatum was also assayed. The results demonstrated that daily administration of Levodopa to PD rats for 21days induced a steady expression of dyskinesia. Coadministration of HSYA with Levodopa significantly ameliorated Levodopa-induced dyskinesia. The combination treatment also prevented the shortening of the motor response duration that defines wearing off motor fluctuations. HSYA also inhibited the increase of expression of the dopamine D3 receptor in the striatum.
These findings demonstrated that HSYA provided anti-dyskinetic relief against Levodopa in a preclinical model of PD via regulating the expression of the dopamine D3 receptor. The combination of Levodopa and HSYA also reduced the likelihood of wearing off development, and may thus support the utility of such compounds for the improved treatment of PD.